SCHEMBL1933893

SCHEMBL1933893

O=C(O)NCc1cnccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
VNN1 O95497 2/20 0.51
NAMPT P43490 2/20 0.51
CYP2C9 P11712 1/20 0.51
CHRM4 P08173 1/20 0.44
HPGDS O60760 1/20 0.44
KDM4E B2RXH2 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
HCAR2 Q8TDS4 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
SPR P35270 1/20 0.43
IDO1 P14902 1/20 0.42
PIK3CA P42336 1/20 0.42
MAPK1 P28482 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29884167 0.83 RECQL (0.53) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL21246171 0.83 RECQL (0.53) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL29602711 0.83 NPSR1 (0.50) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL3003567 0.83 NPSR1 (0.50) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL3003564 0.83 HDAC3 (0.50) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL23022741 0.83 HDAC3 (0.50) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL23070376 0.81 VNN1 (0.49) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL19210478 0.80 HPGDS (0.50) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL15580188 0.80 HDAC3 (0.48) HDAC3HDAC1HDAC2HDAC6VNN1
SCHEMBL4992989 0.80 HDAC3 (0.48) HDAC3HDAC1HDAC2HDAC6VNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102858743-B Spiro-condensed cyclohexane derivatives as HSL inhibitors useful for the treatment of diabetes HOFFMANN LA ROCHE 2015-06-10 CN claimed
US-8440710-B2 HSL inhibitors useful in the treatment of diabetes HOFFMANN-LA ROCHE INC. (US) 2013-05-14 US claimed
CN-102858743-A Spiro-condensed cyclohexane derivatives as HSL inhibitors useful for the treatment of diabetes HOFFMANN LA ROCHE 2013-01-02 CN claimed
EP-2488493-A1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES F. Hoffmann-La Roche AG (CH) 2012-08-22 EP claimed
WO-2011045292-A1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2011-04-21 WO claimed
CN-102858743-B Spiro-condensed cyclohexane derivatives as HSL inhibitors useful for the treatment of diabetes HOFFMANN LA ROCHE 2015-06-10 CN disclosed
EP-2488493-B1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES HOFFMANN LA ROCHE (CH) 2015-04-15 EP disclosed
US-8440710-B2 HSL inhibitors useful in the treatment of diabetes HOFFMANN-LA ROCHE INC. (US) 2013-05-14 US disclosed
CN-102858743-A Spiro-condensed cyclohexane derivatives as HSL inhibitors useful for the treatment of diabetes HOFFMANN LA ROCHE 2013-01-02 CN disclosed
EP-2488493-A1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES F. Hoffmann-La Roche AG (CH) 2012-08-22 EP disclosed
WO-2011068899-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-09 WO disclosed
WO-2011045292-A1 SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2011-04-21 WO disclosed